Enochian Biosciences Inc (ENOB) Director Henrik Gronfeldt-Sorensen Purchases 50,000 Shares

Enochian Biosciences Inc (OTCMKTS:ENOB) Director Henrik Gronfeldt-Sorensen acquired 50,000 shares of the firm’s stock in a transaction on Thursday, January 10th. The shares were acquired at an average price of $2.00 per share, with a total value of $100,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of ENOB stock traded up $0.90 on Friday, hitting $9.25. The stock had a trading volume of 202,653 shares, compared to its average volume of 81,111. Enochian Biosciences Inc has a 52-week low of $3.32 and a 52-week high of $9.50.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.themarketsdaily.com/2019/01/12/enochian-biosciences-inc-enob-director-henrik-gronfeldt-sorensen-purchases-50000-shares.html.

Enochian Biosciences Company Profile

Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.

Featured Story: How to Trade Using Analysts Ratings

Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply